Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

Neurology

Volumn 76, Issue 14, 2011, Pages 1214-1221

  Kowarik, M C ^a   Pellkofer, H L ^b   Cepok, S ^a   Korn, T ^a   Kumpfel T ^b   Buck, D ^a   Hohlfeld, R ^b   Berthele, A ^a   Hemmer, B ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AZATHIOPRINE; BETA INTERFERON; FINGOLIMOD; IMMUNOGLOBULIN G; NATALIZUMAB; OLIGOCLONAL BAND;

ADULT; ALBUMIN BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BLOOD; BLOOD SAMPLING; CD4 CD8 RATIO; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FLOW CYTOMETRY; HERPES VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS DETECTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; T-LYMPHOCYTES; YOUNG ADULT;

EID: 79954611536     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182143564     Document Type: Article

References (16)

1. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.
2. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140. (Pubitemid 44394919)
3. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296:346-349. (Pubitemid 34303689)
4. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427:355-360. (Pubitemid 38133663)
5. Suzuki S, Enosawa S, Kakefuda T, et al. Immunosuppressive effect of a new drug, FTY720, on lymphocyte responses in vitro and cardiac allograft survival in rats. Transpl Immunol 1996;4:252-255. (Pubitemid 26340578)
6. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats: I: FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol 1998;160:5037-5044. (Pubitemid 28215340)
7. Massberg S, von Andrian UH. Fingolimod and sphingosine- 1-phosphate: modifiers of lymphocyte migration. N Engl J Med 2006;355:1088-1091. (Pubitemid 44394915)
8. Bohler T, Waiser J, Schuetz M, Neumayer HH, Budde K. FTY720 exerts differential effects on CD4-and CD8-T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol Dial Transplant 2004;19: 702-713.
9. Stuve O, Marra CM, Bar-Or A, et al. Altered CD4-/ CD8-T-cell ratios in cerebrospinal fluid of natalizumabtreated patients with multiple sclerosis. Arch Neurol 2006; 63:1383-1387.
10. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747. (Pubitemid 43673151)
11. Cepok S, von Geldern G, Grummel V, et al. Accumulation of class switched IgD-IgM- memory B cells in the cerebrospinal fluid during neuroinflammation. J Neuroimmunol 2006;180:33-39. (Pubitemid 44692322)
12. Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008;71: 1350-1354.
13. Vaessen LM, Van Besouw NM, Mol WM, Ijzermans JN, Weimar W. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naive T cells, memory T cells and NK cells. Transpl Immunol 2006;15:281-288.
14. Cinamon G, Matloubian M, Lesneski MJ, et al. Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat Immunol 2004;5:713-720. (Pubitemid 39023303)
15. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-1267.
16. Meno-Tetang GM, Li H, Mis S, et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino- 2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 2006;34:1480-1487. (Pubitemid 44285388)